Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phage cocktail targeting Klebsiella pneumoniae
- Development stage
- Unknown
- Lead developer
- Locus Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Intravesical, Inhalation
01
Overview
A phage cocktail targeting *Klebsiella pneumoniae* is a therapeutic approach that uses a combination of multiple bacteriophages (viruses that infect and kill bacteria) to specifically target and lyse *Klebsiella pneumoniae*. This strategy is being actively developed as an alternative or adjunct to traditional antibiotics, particularly for treating infections caused by multidrug-resistant (MDR) strains, such as carbapenem-resistant *K. pneumoniae* (CRKP). [5, 7, 16] The use of a 'cocktail' containing several different phages helps to broaden the spectrum of activity against various strains of the bacterium and reduces the likelihood of the bacteria developing resistance. [2, 3] Some advanced approaches involve engineering the phages with CRISPR-Cas3 technology to enhance their bactericidal activity (a crPhage™) or using them in synergy with antibiotics to increase efficacy. [1, 9, 17] While phage therapy has been used compassionately in some clinical cases, it is largely in the preclinical and early clinical stages of development for *K. pneumoniae* infections. [2, 4, 6]
- Other names
- phage cocktail targeting Klebsiella pneumoniae
02
Targets
K1 CPS (Klebsiella pneumoniae capsular polysaccharide serotype K1)
Beyond the preview
Go deeper on phage cocktail targeting Klebsiella pneumoniae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phage cocktail targeting Klebsiella pneumoniae.